A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models

Diabetes
Garret J EtgenRaymond F Kauffman

Abstract

A novel nonthiazolidinedione dual peroxisome proliferator- activated receptor (PPAR)-alpha/gamma agonist, LY465608, was designed to address the major metabolic disturbances of type 2 diabetes. LY465608 altered PPAR-responsive genes in liver and fat of db/db mice and dose-dependently lowered plasma glucose in hyperglycemic male Zucker diabetic fatty (ZDF) rats, with an ED(50) for glucose normalization of 3.8 mg small middle dot kg(-1) small middle dot day(-1). Metabolic improvements were associated with enhanced insulin sensitivity, as demonstrated in female obese Zucker (fa/fa) rats using both oral glucose tolerance tests and hyperinsulinemic-euglycemic clamps. Further characterization of LY465608 revealed metabolic changes distinct from a selective PPAR-gamma agonist, which were presumably due to the concomitant PPAR-alpha agonism, lower respiratory quotient, and less fat accumulation, despite a similar impact on glycemia in male ZDF rats. In addition to these alterations in diabetic and insulin-resistant animals, LY465608 dose-dependently elevated HDL cholesterol and lowered plasma triglycerides in human apolipoprotein A-I transgenic mice, demonstrating that this compound significantly improves primary cardiovascular risk fac...Continue Reading

References

Jul 1, 1995·The Journal of Clinical Investigation·T A BuchananW A Hsueh
Jul 20, 1994·JAMA : the Journal of the American Medical Association·R J KuczmarskiC L Johnson
Oct 15, 1996·The Journal of Clinical Investigation·R E LawW A Hsueh
Apr 29, 1997·Proceedings of the National Academy of Sciences of the United States of America·S A KliewerJ M Lehmann
May 20, 1998·The Journal of Clinical Endocrinology and Metabolism·J MinamikawaH Koshiyama
May 9, 2000·Biochemical and Biophysical Research Communications·E ChaputA D Edgar
May 20, 2000·FEBS Letters·M D LeibowitzJ Auwerx
May 29, 2000·The Journal of Biological Chemistry·M Guerre-MilloB Staels
Jun 1, 2000·Metabolism: Clinical and Experimental·G J Etgen, B A Oldham
Aug 10, 2000·Medicinal Research Reviews·K W Buchan, D G Hassall
Aug 11, 2000·Diabetes Care·S AkazawaK Eguchi
Apr 20, 2001·Proceedings of the National Academy of Sciences of the United States of America·W R OliverT M Willson

❮ Previous
Next ❯

Citations

Feb 27, 2009·Basic Research in Cardiology·Roberta A GottliebRobert M Mentzer
Sep 29, 2005·Current Diabetes Reports·Riccardo Perfetti, Eugenio D'Amico
Sep 1, 2007·Hepatology International·David van der Poorten, Jacob George
Apr 13, 2005·Atherosclerosis. Supplements·Philip Barter
Aug 26, 2006·Nature Clinical Practice. Nephrology·Usha PanchapakesanCarol A Pollock
May 27, 2005·International Journal of Obesity : Journal of the International Association for the Study of Obesity·M C CarmonaL Pénicaud
Aug 19, 2007·Journal of Cardiovascular Pharmacology·Eyal Leibovitz, Ernesto L Schiffrin
Dec 21, 2004·International Journal of Clinical Practice·A S Wierzbicki
Jan 1, 2004·The Journal of Clinical Investigation·Mitchell A Lazar
Apr 24, 2007·Osteopathic Medicine and Primary Care·Steven EdelmanSusan Renda
Mar 16, 2011·Cardiology Research and Practice·Saeid Golbidi, Ismail Laher
Sep 12, 2008·PPAR Research·Tianxin Yang, Sunhapas Soodvilai
Jan 25, 2007·Expert Opinion on Investigational Drugs·Jerry R Colca
Dec 10, 2003·Expert Opinion on Emerging Drugs·Anthony S Wierzbicki
Jun 22, 2006·Expert Opinion on Investigational Drugs·Rajesh S Savkur, Anne R Miller
Oct 27, 2004·Expert Opinion on Investigational Drugs·Anthony S Wierzbicki
Mar 1, 2006·Expert Opinion on Investigational Drugs·Guenther Boden, Meijuan Zhang
Oct 9, 2009·Bioorganic & Medicinal Chemistry Letters·Atul KumarArvind K Srivastava
Mar 11, 2008·European Journal of Medicinal Chemistry·Juanhong YuRuyun Ji
Dec 7, 2007·Best Practice & Research. Clinical Endocrinology & Metabolism·Barbara Gross, Bart Staels
Dec 8, 2004·Bioorganic & Medicinal Chemistry Letters·José A MartínAlan M Warshawsky
Jun 24, 2004·European Journal of Pharmacology·Hideaki MinouraSeitaro Mutoh
Oct 26, 2005·Bioorganic & Medicinal Chemistry Letters·Tadigoppula NarenderRamesh Chandra
Jul 9, 2005·Trends in Endocrinology and Metabolism : TEM·Christodoulos S FlordellisAthanasios G Papavassiliou
Feb 13, 2003·Obesity Research·Reeba K VikramadithyanRanjan Chakrabarti
Aug 31, 2004·Diabetes Care·Guenther Boden, Markku Laakso
Aug 21, 2007·Diabetes·Maria Carmen CarmonaUNKNOWN Consortium of the French Ministry of Research and Technology
May 14, 2004·European Journal of Pharmacology·Ranjan ChakrabartiRamanujam Rajagopalan
Apr 13, 2007·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Pitchai BalakumarManjeet Singh
Jan 27, 2007·Toxicological Sciences : an Official Journal of the Society of Toxicology·Yin GuoTimothy P Ryan
Mar 5, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Erik G LundCarl P Sparrow

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.